Amid Trump’s dismantling of DEI, Roche wiped diversity targets from the website of its US subsidiary, Genentech, in mid-February. Basel-based competitor Novartis also said this week it was getting rid ...

Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) Fabhalta is the only oral alternative complement pathway ...

While the clinical dementia findings did not reach statistical significance, they were the first to provide a hint that early ...

Shares of Puma Biotechnology PBYI have rallied 35.3% in the past six months against the industry’s decline of 9.2%. The ...

An experimental drug appears to reduce the risk of Alzheimer's-related dementia in people destined to develop the disease in their 30s, 40s or 50s, according to the results of a new study. The ...

Thanks to the spending growth cap, the U.K. government in December 2024 announced that companies would need to pay a 22.9% ...

The FDA wants to end bulk production of copycat versions of weight loss drugs; telehealth companies and compounding ...

Rutgers researchers found that increased brown fat improves longevity and exercise capacity in mice. They aim to develop a ...

An experimental drug appears to reduce the risk of Alzheimer's-related dementia in people destined to develop the disease in ...

We recently published a list of 10 Best Diabetes Stocks To Buy According to Billionaires. In this article, we are going to ...

Swiss drugmaker Roche has abandoned global diverse workforce targets and compatriot Novartis is ending its use of diverse ...

A popular over-the-counter (OTC) acne treatment sold at Walgreens and other U.S. retailers is being recalled because it was ...